The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
Top Cited Papers
Open Access
- 1 January 2020
- journal article
- conference paper
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 6 (1) , 116-124
Abstract
Most patients with metastatic breast cancer have tumors that are hormone receptor (HR)-positive and are initially treated with endocrine therapy (ET).1-4 Although ET is an efficacious and well-tolerated therapy in most patients, resistance to ET and subsequent disease progression remains a major challenge.2 In an effort to improve treatment options, cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors in combination with ET have emerged as a standard-of-care treatment for patients with HR-positive, ERBB2 (formerly HER2)-negative advanced breast cancer (ABC) (eg, inoperable locally advanced or metastatic breast cancer).5-8Keywords
This publication has 27 references indexed in Scilit:
- Corrigendum to “3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)” [Breast 31 (February 2017) 244–259]The Breast, 2017
- Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosisBreast Cancer Research and Treatment, 2016
- Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology GuidelineJournal of Clinical Oncology, 2016
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialThe Lancet Oncology, 2016
- Palbociclib in Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2015
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabineInvestigational New Drugs, 2014
- Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directionsWorld Journal of Clinical Oncology, 2014
- Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcomeBreast Cancer Research and Treatment, 2013
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Prognostic factors in 1038 women with metastatic breast cancerAnnals of Oncology, 2008